Gazyva® (obinutuzumab) receives positive reimbursement recommendation from the Institut national d'excellence en santé et en services sociaux (INESSS) for persons with active lupus nephritis

AI Briefing

• – • Gazyva receives positive reimbursement recommendation from INESSS for active lupus nephritis treatment.
• – • The treatment is expected to benefit patients with this condition in France.
• – • The recommendation is a significant milestone for Roche Canada's Gazyva treatment.